Atorvastatin calcium
Key facts
| Invented name |
Sortis and associated names
|
| Active substance |
Atorvastatin calcium
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/53/2008
|
| PIP number |
Atorvastatin calcium
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Pure hypercholesterolaemia (heterozygous, homozygous, or otherwise primary hypercholesterolaemia), combined (mixed) hyperlipidaemia; prevention of cardiovascular events
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Limited
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-C-000073-PIP01-07
|
| Compliance opinion date |
13/11/2009
|
| Compliance outcome |
positive
|